Will Mirabegron Pass Muster In Overactive Bladder?
By
Emily Hayes / Email the Author / “The Pink Sheet” DAILY Feb. 8, 2012
Word Count: 546 / Article # 14120208002
Executive Summary
Astellas aims to muscle in to a growing disease space dominated by muscarinic receptor agonists with its beta-3 agonist mirabegron (YM178) – but first it must get by an FDA advisory committee review.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.